Asp isotopes inc. enters into 25-year supply agreement valued at up to $27 million per annum for highly enriched molybdenum-100

Boca raton, fl / accesswire / november 29, 2022 / asp isotopes inc. (nasdaq:aspi) ("aspi", the "company", "us", "we" or "our"), an advanced materials company dedicated to the development of technology and processes designed to produce isotopes used in multiple industries, today announced that the company has entered into 25-year supply agreement for highly enriched molybdenum-100 (mo-100) with bricem (beijing research institute of chemical engineering metallurgy). mo-100 is used in the preparation of radiopharmaceuticals used in nuclear medicine procedures to diagnose heart disease and cancer, to study organ structure and function, and to perform other important medical applications.
ASPI Ratings Summary
ASPI Quant Ranking